AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.
You may also be interested in...
Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering
Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.
AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013
Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.